Crizotinib in the treatment of non‐small cell lung cancer

02/2018

MUDr. Ondřej Venclíček

Klinika nemocí píicních a tuberkulózy LF MU a FN Brno

SUMMARY

Crizotinib is an ALK, ROS1 and MET tyrosine kinase inhibitor approved for the treatment of ALK and ROS1 positive, advanced, non-small cell lung cancer, both in the first line of treatment and in previously treated patients. The following text presents the results of studies that showed the role of crizotinib in the treatment of non-small cell lung cancer, its different molecular targets (ALK, ROS1 and MET), mechanism of action and side effects.

KEY WORDS

crizotinib, tyrosine kinase inhibitor, non-small cell lung cancer